Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of YC-6 in Healthy Chinese Adults
NCT03358901Phase 1Unknown
- Sponsor
- Guangzhou Cellprotek Pharmaceutical Co., Ltd.
- Start
- Dec 2016
- Primary completion
- Dec 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in ischemic stroke comparing YC-6 with Vehicle (2 arms). Primary endpoint: Number of participants who experience treatment-related adverse events (AEs) and serious adverse events (SAEs). Status: unknown.
02
Drugs
androtriol
03
Conditions
ischemic stroke
Beyond the preview
Go deeper on NCT03358901.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03358901.